Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03030768 · ClinicalTrials.gov registry record

Safer Conception Intervention for HIV-1 Serodiscordant Couples

A clinical trial of Pregnancy, High Risk and HIV Seropositivity, sponsored by University of Washington.

Completed
Registry status
74
Enrollment target
2
Study locations

NCT03030768 is a study of Pregnancy, High Risk and HIV Seropositivity that has completed, run by University of Washington. The registered enrollment target is 74 participants, below the 314-participant average among 20 other Pregnancy, High Risk trials with a reported enrollment target (76% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03030768, a study of Pregnancy, High Risk and HIV Seropositivity, has completed, sponsored by University of Washington.

COMPLETED
Registry status
74 participants
Enrollment target
2
Study locations

Study Summary

The greatest burden of the HIV-1 epidemic lies in sub-Saharan Africa, where a substantial proportion of infections occur in long-term heterosexual HIV-1 serodiscordant partnerships. Such couples face a difficult dilemma when considering their desire to have children: forego condom use, attempt to conceive and risk HIV-1 transmission or continue condom use and relinquish their childbearing desires. Based on evidence from rigorous clinical trials demonstrating the strong efficacy of individual interventions for HIV-1 prevention and formative work with HIV-1 serodiscordant couples and clinicians with expertise in HIV-1 prevention and reproductive health in the Kenyan context, this study pilots a safer conception intervention that focuses on antiretrovirals (as antiretroviral therapy \[ART\] taken by the HIV-1 infected partner and pre-exposure prophylaxis \[PrEP\] taken by the HIV-1 uninfected partner) and timed condomless sex. Additional strategies for couples include diagnosis and treatment of STIs and male circumcision. mHealth tools, including SMS and mobile applications are novel and very popular among Kenyans to ease the burden of addressing health problems. This safer conception intervention incorporates mHealth tools to improve couples' experiences tracking fertility indicators and communicating with providers about their readiness to practice safer conception. SMS surveys to collect daily information from women about their fertility signs and SMS messages are used to reinforce HIV-1 prevention, including condom use for couples during periods that do not have a high likelihood of fertility. An in-clinic mobile application is used to improve clinician-patient counseling and assessments of couple readiness to practice safer conception. To inform future engagement of mHealth tools, the investigators will prospectively evaluate clinician and patient experiences using SMS surveys and the tablet application. Couples with immediate fertility intentions will be followe

Interventions

  • DRUG PrEP
  • BEHAVIORAL Counseling on timed condomless sex, ART and PrEP adherence

Study Locations (2)

Washington

  • University of Washington, Coordinating Center - Seattle

Other

  • Partners in Health, Research and Development - Thika

Trial Details

FieldValue
Enrollment Target 74 participants
Start Date 2016-02
Est. Completion 2018-07

Sponsor

University of Washington

1,048 total trials

What the Registry Record Tells You About NCT03030768

The ClinicalTrials.gov registry entry for NCT03030768 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 314-participant average among 20 other Pregnancy, High Risk trials with a reported enrollment target (76% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Pregnancy, High Risk appearing as the primary indexed condition, and to 2 interventions - of which PrEP is the first listed.

NCT03030768 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Washington, Other.

Frequently Asked Questions

What is clinical trial NCT03030768 about?

NCT03030768 is a clinical study titled "Safer Conception Intervention for HIV-1 Serodiscordant Couples". The greatest burden of the HIV-1 epidemic lies in sub-Saharan Africa, where a substantial proportion of infections occur in long-term heterosexual HIV-1 serodiscordant partnerships. Such couples face a difficult dilemma when considering their desire to have children: forego condom use, attempt to co...

What is the current status of trial NCT03030768?

This trial is currently completed. The enrollment target is 74 participants. The study started on 2016-02. Estimated completion is 2018-07.

What conditions does trial NCT03030768 study?

This clinical trial studies the following conditions: Pregnancy, High Risk, HIV Seropositivity.

What interventions are being tested in trial NCT03030768?

The interventions under investigation include: PrEP (DRUG), Counseling on timed condomless sex, ART and PrEP adherence (BEHAVIORAL).

Who is sponsoring clinical trial NCT03030768?

This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03030768 being conducted?

This trial has 2 study locations across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pregnancy, High Risk

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.